Analgesia
Conditions
Keywords
C-CELA, newborn, analgesia, epidural, pain
Brief summary
The goal of this clinical trial is to learn about the pharmacokinetics of levobupivacaine in newborns during the continus caudal epidural analgesia. This type of analgesia is used for severly ill newborns. There is a need to lower the opioid doses for this population who is undergoing the surgery due to the life threading indication. In some cases it is considered to use the epidural analgesia for the sake of the patient. The main question is: Is the commonly used dosing of 0,25% levobupivacaine in dose 0,2-0,3mg/kg/h the ideal dosing for these patients? Is this type of dosing of epidural analgesia safe and effective for newborns?
Interventions
DIAGNOSTIC_TESTBlood draw
The blood draws in specified time points
Sponsors
University Hospital, Motol
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
PK study
Eligibility
Sex/Gender
ALL
Age
1 Hours to 5 Weeks
Healthy volunteers
No
Inclusion criteria
* Obtained informed consent of parent(s)/legal representative(s) * Age younger than 45thweek of PMA * Age older than 25thweek of PMA * body weight (BW) more than 500g * Previous or planned operation with great demand on POPM * Other diseases demanding great POPM (even without any need of surgery) * Vital functions of the patient will be stable and there will be no suspicion, that patient current condition might be worsen by insertion of c-CELA (every patient will be discussed with attending physician )
Exclusion criteria
* Decline of informed consent by parent(s) legal representative * Age older than 45thweek of PMA * Age younger than 25th week of PMA * body weight (BW) lower than 500g * Congenital malformation of caudal part of spine ( spina bifida occulta , meningocele, meningomyelocele) * Disease or congenital malformation significantly restricting liver functions (Elevation of liver enzymes more than twice above the physiological range of the corresponding PMA) * Disease or congenital malformation significantly restricting kidney functions (Elevation of urea and creatinine enzymes more than twice above the physiological range of the corresponding PMA) * Clinical condition, which doesn't long-term POPM * Meningism * Patients with proven withdrawal syndrome caused by opiate administration * High risk of bleeding during insertion (coagulopathy) or known administrated anticoagulants which might be still active in the time of insertion of c-CELA * Substantial anemia (under 90g/l), which could lead to blood transfusion due to blood drawing * frequent blood tests associated with the treatment of the patient(with blood samples necessary for the purposes of the study together), which would exceed maximum * any hemodynamically unstable condition (for example septic shock)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety | 144 hours | AE, SAE monitoring, opioid intake monitoring |
| Effectivity | 144 hours | Pain managment monitoring - Comfort Neo Scale |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Neurotoxicity | up to 5 years | Follow up visits with basic neurology examination |
Countries
Czechia
Outcome results
None listed